lapatinib has been researched along with veliparib in 3 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (veliparib) | Trials (veliparib) | Recent Studies (post-2010) (veliparib) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 325 | 87 | 286 |
Protein | Taxonomy | lapatinib (IC50) | veliparib (IC50) |
---|---|---|---|
Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.0469 | |
Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | 1.9027 | |
Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.0688 | |
Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 3.4837 | |
Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 2.089 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Cooper, T; Nowsheen, S; Stanley, JA; Yang, ES | 1 |
Acosta, EP; Caterinicchia, V; Chen, D; Della Manna, DL; Falkson, CI; Forero-Torres, A; Li, Y; May, JE; Nabell, LM; Olariu, E; Rocque, GB; Stringer-Reasor, EM; Vaklavas, C; Yang, ES | 1 |
1 trial(s) available for lapatinib and veliparib
Article | Year |
---|---|
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Disease Management; Drug Monitoring; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
2 other study(ies) available for lapatinib and veliparib
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Breaks, Double-Stranded; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Transport; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinational DNA Repair; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |